Want to see TCMD full AI Analyst Report?
TCMD Stock Chart & Stats
$27.48
$0.28(1.02%)
At close: 4:00 PM EDT
$27.48
$0.28(1.02%)
Day’s Range― - ―
52-Week Range$12.12 - $37.77
Previous Close$27.76
Volume126.76K
Average Volume (3M)237.52K
Market Cap
$657.29M
Enterprise Value$631.20
Total Cash (Recent Filing)$69.85M
Total Debt (Recent Filing)$14.36M
Price to Earnings (P/E)22.0
Beta0.67
Next Earnings
Nov 09, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.10
Shares Outstanding22,556,260
10 Day Avg. Volume209,219
30 Day Avg. Volume237,524
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)3.03
Price to Sales (P/S)2.01
P/FCF Ratio16.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$39.00Price Target Upside41.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.14
Revenue Forecast (FY)$364.81M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetThe company’s dramatic deleveraging to about $14.4M TTM and a debt-to-equity near 0.06 materially increases financial flexibility. This durable strength supports multi-year investment in commercialization, clinical programs, and opportunistic M&A without near-term refinancing risk.
High, Expanding Gross MarginsSustained high gross margins (mid-70s guidance and historical levels) indicate strong product-level economics and pricing power in pneumatic compression systems and consumables. Durable margin structure underpins long-term operating profitability even as SG&A investments scale.
Durable Demand & Portfolio ExpansionConsistent double-digit lymphedema growth and multi-year AffloVest TTM growth reflect durable clinical adoption and recurring consumable-driven revenue. Combined with product initiatives (MyoSleeve VA/DoD distribution and LymphaTech) this widens addressable market and deepens federal and clinical channels.
Bears Say
Reimbursement DependenceRevenue realization depends heavily on third-party payor policies and documentation. New Medicare prior authorization requirements are a structural reminder that coverage changes, approvals, and administrative burdens can meaningfully slow adoption and increase sales cycle duration across payors.
Channel Concentration RiskDependence on a few large DME partners for airway-clearance distribution creates persistent execution risk: inventory or purchasing shifts by these partners can produce volatile quarter-to-quarter revenue and weaken predictability of the indirect channel over time.
Softening Cash-flow MomentumAlthough cash generation remains positive, TTM operating and free cash flow have declined versus 2025 and OCF now trails net income. This indicates working-capital and timing pressures and means management must balance growth investments, strategic payments, and buybacks while preserving long-term liquidity.
Tactile Systems Technology News
TCMD FAQ
What was Tactile Systems Technology’s price range in the past 12 months?
Tactile Systems Technology lowest stock price was $12.12 and its highest was $37.77 in the past 12 months.
What is Tactile Systems Technology’s market cap?
Tactile Systems Technology’s market cap is $657.29M.
When is Tactile Systems Technology’s upcoming earnings report date?
Tactile Systems Technology’s upcoming earnings report date is Nov 09, 2026 which is in 89 days.
How were Tactile Systems Technology’s earnings last quarter?
Tactile Systems Technology released its earnings results on Aug 10, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.135 by $0.205.
Is Tactile Systems Technology overvalued?
According to Wall Street analysts Tactile Systems Technology’s price is currently Undervalued.
Does Tactile Systems Technology pay dividends?
Tactile Systems Technology does not currently pay dividends.
What is Tactile Systems Technology’s EPS estimate?
Tactile Systems Technology’s EPS estimate is 0.3.
How many shares outstanding does Tactile Systems Technology have?
Tactile Systems Technology has 22,556,260 shares outstanding.
What happened to Tactile Systems Technology’s price movement after its last earnings report?
Tactile Systems Technology reported an EPS of $0.34 in its last earnings report, beating expectations of $0.135. Following the earnings report the stock price went down -17.124%.
Which hedge fund is a major shareholder of Tactile Systems Technology?
Currently, no hedge funds are holding shares in TCMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tactile Systems Technology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.00 (41.92% Upside)
$39.00 (41.92% Upside)
Blogger Sentiment
Bullish
TCMD Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 176.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $113.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
163.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.90%
Trailing 12-Months
Company Description
Tactile Systems Technology
Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.
TCMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid overall momentum driven by a strong lymphedema business, meaningful margin and profitability expansion, supportive clinical evidence publication, and strategic product and distribution initiatives (LymphaTech, MyoSleeve, next‑gen AffloVest). Near-term headwinds are limited and identifiable—chiefly temporary DME inventory management affecting AffloVest, Medicare prior authorization timing effects, and planned expense and strategic cash deployment—while multiyear fundamentals and guidance were maintained/upgraded. Taken together, positives around revenue growth, margin expansion, durable AffloVest TTM growth, and clinical/regulatory progress outweigh the transitory challenges.View all TCMD earnings summariesTCMD Stock 12 Month Forecast
Average Price Target
$39.00
▲(41.92% Upside)
Technical Analysis
Sanuwave Health
―
Viemed Healthcare
―
Outset Medical
―
TriSalus Life Sciences
―
Ceribell, Inc.
―
Ownership Overview
3.57% Insiders
20.55% Mutual Funds
5.88% Other Institutional Investors
51.02% Public Companies and
Individual Investors